dromlakhani Avoid GHRH-arginine test for post-radiation GHD
STEP 1 — Gather Information
Collect history of hypothalamic–pituitary axis radiation (dose, field, timing), clinical signs of GHD (e.g., growth deceleration, low IGF-I), and confirm absence of three other anterior pituitary hormone deficits that would obviate testing.
→ Proceed to assess radiation exposure status.
STEP 2 — Rule In / Rule Out
Determine if the patient received hypothalamic–pituitary axis radiation ≥18 Gy. If yes, rule out GHRH ± arginine testing; if no, proceed to standard provocative testing per non‑cancer protocols.
→ Branch to irradiated vs. non‑irradiated pathway.
STEP 3 — Classify or Stratify
For irradiated patients, plan alternative provocative testing (insulin tolerance test, glucagon) or clinical assessment; for non‑irradiated patients, apply standard GH cut‑offs (e.g., ITT <5 µg/L, glucagon <3 µg/L).
→ Select appropriate diagnostic strategy.
STEP 4 — Decide
In irradiated patients, do not order GHRH ± arginine; instead perform insulin tolerance test or glucagon test with validated cut‑offs, or rely on clinical diagnosis if testing is contraindicated.
→ Finalize testing plan or defer to clinical judgment.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on GHRH alone after radiation due to false‑negative GH responses; avoid arginine‑only testing; do not use an IGF‑I cutoff of –2 SD without confirmatory testing; remember that obesity, glucocorticoids, or hypothyroidism can blunt GH secretion and yield misleading results.
Concrete Clinical Example
A 16‑year‑old medulloblastoma survivor who received 24 Gy craniospinal radiation at age 5 presents with slowed growth velocity and IGF‑I –1.5 SD. The clinician considers GHD testing but, recalling the radiation exposure, opts for an insulin tolerance test instead of GHRH‑arginine.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-01175